Table 4. Impact of prognostic factors on treatment results by univariate analysis.
| Items | 5y-LFFS | 5y-RFFS | 5y-DFFS | 5y-OS | ||||
|---|---|---|---|---|---|---|---|---|
| % | p | % | p | % | p | % | p | |
| Gender | ||||||||
| Male | 85.1 | .662 | 93.9 | .679 | 74.6 | .433 | 62.9 | .211 |
| Female | 88.4 | 95.5 | 80.6 | 73.4 | ||||
| Age | ||||||||
| ≥50 y | 83.4 | .599 | 94.4 | .944 | 78.6 | .645 | 55.2 | .011 |
| <50y | 87.9 | 94.4 | 74.1 | 73.9 | ||||
| Involvement of cranial nerves | ||||||||
| NO | 89.0 | .049 | 95.8 | .176 | 76.0 | .840 | 71.3 | .033 |
| YES | 76.9 | 90.1 | 77.3 | 49.3 | ||||
| N classification | ||||||||
| N0–1 | 87.5 | .922 | 97.0 | .227 | 82.0 | .188 | 74.4 | .347 |
| N2–3 | 84.8 | 92.5 | 72.3 | 59.5 | ||||
| Metastasis to (RLN) | ||||||||
| NO | 83.4 | .307 | 97.3 | .408 | 74.5 | .971 | 70.7 | .585 |
| YES | 86.5 | 93.5 | 76.7 | 63.8 | ||||
| Concurrent chemoradiotherapy | ||||||||
| NO | 85.6 | .762 | 90.6 | .162 | 77.4 | .788 | 62.4 | .463 |
| YES | 86.0 | 96.3 | 75.9 | 66.8 | ||||
| Boost | ||||||||
| NO | 87.9 | .368 | 95.0 | .478 | 76.7 | .975 | 66.7 | .422 |
| YES | 80.4 | 92.6 | 74.6 | 60.7 | ||||
| Volume of GTVnx | ||||||||
| >50 ml | 75.2 | .004 | 92.8 | .453 | 78.4 | .991 | 52.8 | .008 |
| ≤50ml | 94.2 | 95.5 | 77.2 | 78.7 | ||||
Abbreviations: RLN, retropharyngeal lymph nodes; GTVnx, gross tumor volume of the nasopharynx; LFFS, local failure-free survival; RFFS, regional failure-free survival; DFFS, distant failure-free survival; OS, overall survival.